About Stenabolic (SR-9009) Ultima Pharmaceuticals
Stenabolic (SR-9009) is a Rev-Erbα nuclear receptor agonist developed by Scripps Research Institute for investigating circadian rhythm regulation and metabolic pathways in laboratory settings. Unlike SARMs, this compound functions as a synthetic agonist of the Rev-Erbα nuclear receptor, a key component of the molecular circadian clock. Research applications focus on examining how Rev-Erbα activation influences metabolic gene expression, mitochondrial biogenesis, and cellular energy homeostasis. Scientists at Stroid UK Shop supply this compound for advanced metabolic research protocols requiring high-purity synthetic modulators.
Laboratory Applications
Research teams investigate SR-9009’s effects on circadian biology through studies examining metabolic flexibility, lipid oxidation pathways, and glucose homeostasis in cellular models. The compound’s mechanism involves binding to Rev-Erbα receptors in liver, muscle, and adipose tissues, modulating expression of genes controlling circadian rhythms and energy expenditure. Studies published in metabolic journals demonstrate its utility in examining how nuclear receptor activation influences mitochondrial function and fatty acid metabolism. Researchers studying metabolic disorders often examine this compound alongside other modulators from our stenabolic collection and broader SARMs research catalogue. Laboratory protocols frequently combine SR-9009 with peptide modulators to examine complex metabolic interactions.
Technical Specifications
| Chemical Name | SR-9009 (Stenabolic) |
|---|---|
| CAS Number | 1379686-30-2 |
| Molecular Formula | C₂₀H₂₄ClN₃O₄S |
| Molecular Weight | 437.94 g/mol |
| Mechanism | Rev-Erbα nuclear receptor agonist |
| Manufacturer | Ultima Pharmaceuticals |
| Storage | Room temperature, dry conditions |
| Solubility | DMSO, ethanol (verify with supplier) |
Research Use Compliance
This SR-9009 preparation is manufactured exclusively for in-vitro laboratory research applications. The compound is not intended for human consumption, therapeutic use, or any application outside controlled laboratory environments. Researchers must ensure proper handling protocols, appropriate disposal methods, and compliance with institutional research guidelines. All studies should follow established research ethics and safety procedures for synthetic nuclear receptor modulators.
